
In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, academic clinical lecturer in rheumatology, University of Leeds, was joined at the European Alliance of Associations for Rheumatology (EULAR) 2026 annual congress in London by Laurence Duquenne, MD, a rheumatology researcher, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, an investigator on one of the meeting's standout studies to examine whether baseline naïve CD4+ T cell frequency can identify which newly diagnosed patients with rheumatoid arthritis (RA) are unlikely to respond to methotrexate monotherapy, and whether adding a biologic at the outset can close that gap.Click here to watch the episode.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

2: Joint Ventures Recaps Influential EULAR Studies in SLE, RA, and More

1: Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B

Liver Lineup: HDV Diagnosis, Bulevirtide, and the Delta Pipeline

Joint Ventures: Lupus Health Inequalities, Growing Burden of ICI-Arthritis at EULAR 2026
Free AI-powered recaps of HCPLive Podcasts and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.